Mechanism ALK inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Aug 2011 |
Target |
Mechanism MST1R inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Mechanism AXL inhibitors [+5] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date28 Mar 2024 |
Sponsor / Collaborator |
Start Date21 Nov 2023 |
Sponsor / Collaborator |
Start Date31 Oct 2023 |
Sponsor / Collaborator |